Immunohistochemistry (IHC) Market Size, Share, Forecast, & Trends Analysis by Offering (Reagents [Fixation, Buffer, Blocking, Antibodies]), Kits, Equipment [Staining, Imaging] Method Process, Application, End User

Description

List of Tables

Immunohistochemistry (IHC) Market Size, Share, Forecast, & Trends Analysis by Offering (Reagents [Fixation, Buffer, Blocking, Antibodies], Kits, Equipment [Staining, Imaging] Method (ABC, CSA, PAP) Process, Application, End User-Global Forecast to 2031

The global immunohistochemistry market is projected to reach $4.08 billion by 2031 at a CAGR of 7.2% from 2024 to 2031.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the global immunohistochemistry market is driven by the increasing prevalence of chronic diseases, among geriatric populations, increasing emphasis on rare diseases, growing awareness toward the importance of early disease diagnosis, rising R&D expenditure, growing demand for drug discovery and development, increasing burden of infectious diseases, increasing funding for research activities and rising healthcare expenditure. However, the lack of standardized protocols is restraining the growth of this market.

Furthermore, inclination toward personalized medicine, innovations in genomics and proteomics, and increasing automation in histochemistry are expected to generate market growth opportunities. However, the availability of alternative technologies is a major challenge in the global immunohistochemistry market.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry in the past three to four years. The key players operating in the immunohistochemistry market are F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), Agilent Technologies, Inc. (U.S.), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (U.S.), Eagle Biosciences, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S), Cell Signaling Technology, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Bio SB Inc. (U.S.), Biocare Medical, LLC. (U.S.), Bio-Genex Laboratories (U.S.), and CANDOR Bioscience GmbH (Germany).

Among all the offerings studied in this report, in 2024, the consumables segment is expected to account for the largest share of 68.4% of the immunohistochemistry market. The large market share of this segment is attributed to the advancements in kits and reagents enabling laboratories to perform multiple tests simultaneously, the rising burden of chronic diseases, and growing research in genetic and rare diseases by biopharmaceutical companies, contract research organizations, and research laboratories.

Among all the methods studied in this report, in 2024, the avidin-biotin complex is expected to account for the largest share of 30.8% of the immunohistochemistry market. The large market share of this segment is attributed to the various advantages of avidin-biotin complexes, such as resistivity to enzymatic reactions, change in pH, temperature, denaturation, and organic reagents, increased detection efficiency, low primary antibody consumption, and less assay time as compared to other methods.

Among all the applications studied in this report, in 2024, the clinical applications segment is expected to account for the largest share of the immunohistochemistry market. The segment's large market share can be attributed to the rising burden of cancer, the rising awareness of the advantages of immunohistochemistry testing for treatment purposes among healthcare professionals, and the increasing number of diagnostic laboratories. For instance, according to the American Cancer Society, around 20 million new cancer cases were newly diagnosed, and 9.7 million individuals died from the cancer worldwide in 2022. The number of cases is expected to reach up to 35 million by 2050. This increases the demand for immunohistochemistry tests for disease detection.

Among all the end users studied in this report, in 2024, the hospitals and diagnostic laboratories segment is expected to account for the largest share of the immunohistochemistry market. This segment's largest share is attributed to the increasing incidences of cancer, high healthcare expenditures, and the increasing number of hospitals in both developed and developing countries. Furthermore, patients' inclination toward hospitals due to well-established infrastructure, availability of skilled professionals, medical facilities, and advanced treatments also support the large market share of hospitals and diagnostic laboratories.

An in-depth analysis of the geographical scenario of the global immunohistochemistry market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. Asia-Pacific is projected to register the highest CAGR of 13.0% during the forecast period. Accelerated growth in emerging countries in Asia-Pacific has relatively increased the emphasis of various governments towards the healthcare sector in terms of increased investments to enhance the accessibility to healthcare facilities and build better healthcare infrastructure.

Scope of the Report:

Immunohistochemistry Market Assessment-by Offering

Consumables
- Reagents
Fixation Reagents
Antigen Retrieval
Buffers
Blocking Reagents
Antibodies
Control Reagents
Chromogenic Substrates
Counterstain
- Other accessories
Equipment
- Staining Systems
- Imaging Systems
- Slide Scanners
- Tissue Microarrays
Services & Software

Note: other accessories include glass slides, racks & vials, mounting media, and organic solvents.

Immunohistochemistry Market Assessment-by Method

Avidin-Biotin Complex
Polymer-Based Immunohistochemistry
Catalyzed Signal Amplification (CSA)
Fluorescyl-tyramide Amplification
Improved Catalyzed Signal Amplification (iCSA)
Multi-Staining Immunohistochemistry
Labeled Streptavidin Biotin (LSAB)
PAP Method

Immunohistochemistry Market Assessment-by Process

Sample Preparation
Antigen Retrieval
Background Blocking
Target Detection
Sample Visualization

Immunohistochemistry Market Assessment-by Application

Research and Other Applications
- Drug Discovery
- Agriculture & Animal Research
- Other Applications
Clinical Applications
- Reproductive Health
- Oncology
- Infectious Disease
- Other Clinical Applications

Note 1: Other applications include food microbiology, microbiota analysis in the beverage industry, and environmental studies.

Note 2: Other clinical applications include the detection of genetic aberrations in neurological disorders, rare diseases, metabolic and immune disorders, and food-borne illnesses.

Immunohistochemistry Market Assessment-by End User

Pharmaceutical & Biotechnology Companies
Hospitals & Diagnostic Laboratories
Academic Institutes & Research Centers
Other End Users

Note: Other end users include forensic laboratories and transfusion laboratories.

Immunohistochemistry Market Assessment-by Geography

North America
- U.S.
- Canada
Europe
- Germany
- France
- U.K
- Italy
- Spain
- Rest of Europe (RoE)
Asia-Pacific (APAC)
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific (RoAPAC)
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa

Product Code: MRHC - 1041284

1. Introduction

1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders

2. Research Methodology

2.1. Research Approach
2.2. Process of Data Collection & Validation
- 2.2.1. Secondary Research
- 2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
2.3. Market Sizing and Forecasting
- 2.3.1. Market Size Estimation Approach
- 2.3.2. Growth Forecast Approach
- 2.3.3. Market Share Analysis
2.4. Assumptions for the Study

3. Executive Summary

4. Factors Affecting Market Growth

4.1. Overview
4.2. Drivers
- 4.2.1. Rising Prevalence of Chronic Diseases Coupled with the Increasing Geriatric Population
- 4.2.2. Increasing Focus on Rare Disease
- 4.2.3. Rising Awareness Regarding Early Disease Diagnosis
- 4.2.4. Increasing Research and Development Expenditure
- 4.2.5. Rising Demand for Drug Discovery and Development
- 4.2.6. Rising Prevalence of Infectious Diseases
- 4.2.7. Increasing Funding for Research Activities
- 4.2.8. Rising Healthcare Expenditure
4.3. Restraints
- 4.3.1. Lack of Standardized Protocols
4.4. Opportunities
- 4.4.1. Increasing Inclination Toward Personalized Medicine
- 4.4.2. Advancements in Genomics and Proteomics
- 4.4.3. Increasing Automation in Immunohistochemistry
4.5. Challenges
- 4.5.1. Availability of Alternative Technology
4.6. Trends
- 4.6.1. AI-Based Histochemistry
- 4.6.2. Use of Multiplex IHC
4.7. Factor Analysis
4.8. Case Studies
4.9. Pricing Analysis
4.10. Regulatory Analysis
- 4.10.1. U.S.
- 4.10.2. Canada
- 4.10.3. Europe
- 4.10.4. China
- 4.10.5. Japan
- 4.10.6. India
- 4.10.7. Latin America
- 4.10.8. Middle East
4.11. Pricing Analysis
4.12. Porter's Five Forces Analysis

5. Immunohistochemistry Market Assessment-by Offering

5.1. Overview
5.2. Consumables
- 5.2.1. Reagents
  - 5.2.1.1. Fixation Reagents
  - 5.2.1.2. Antigen Retrieval
  - 5.2.1.3. Buffers
  - 5.2.1.4. Blocking Reagents
  - 5.2.1.5. Antibodies
  - 5.2.1.6. Control Reagents
  - 5.2.1.7. Chromogenic Substrates
  - 5.2.1.8. Counterstain
- 5.2.2. Other Accessories
5.3. Equipment
- 5.3.1. Staining System
- 5.3.2. Imaging Systems
- 5.3.3. Slide Scanners
- 5.3.4. Tissue Microarrays
5.4. Services & Software

6. Immunohistochemistry Market Assessment-by Method

6.1. Overview
6.2. Avidin-Biotin Complex
6.3. Polymer-Based Immunohistochemistry
6.4. Catalyzed Signal Amplification (CSA)
6.5. Fluorescyl-tyramide Amplification
6.6. Improved Catalyzed Signal Amplification (iCSA)
6.7. Multi-Staining Immunohistochemistry
6.8. Labeled Streptavidin Biotin (LSAB)
6.9. PAP Method

7. Immunohistochemistry Market Assessment-by Process

7.1. Overview
7.2. Sample Preparation
7.3. Antigen Retrieval
7.4. Background Blocking
7.5. Target Detection
7.6. Sample Visualization

8. Immunohistochemistry Market Assessment-by Application

8.1. Overview
8.2. Research and Other Applications
- 8.2.1. Drug Discovery
- 8.2.2. Agriculture & Animal Research
- 8.2.3. Other Applications
8.3. Clinical Applications
- 8.3.1. Reproductive Health
- 8.3.2. Oncology
- 8.3.3. Infectious Disease
- 8.3.4. Other Clinical Applications

9. Immunohistochemistry Market Assessment-by End User

9.1. Overview
9.2. Pharmaceutical & Biotechnology Companies
9.3. Hospitals & Diagnostic Laboratories
9.4. Academic Institutes & Research Centers
9.5. Contract Research Organizations
9.6. Other End Users

10. Immunohistochemistry Market Assessment-by Geography

10.1. Overview
10.2. North America
- 10.2.1. U.S.
- 10.2.2. Canada
10.3. Europe
- 10.3.1. Germany
- 10.3.2. France
- 10.3.3. U.K.
- 10.3.4. Italy
- 10.3.5. Spain
- 10.3.6. Rest of Europe
10.4. Asia-Pacific
- 10.4.1. Japan
- 10.4.2. China
- 10.4.3. India
- 10.4.4. Australia
- 10.4.5. South Korea
- 10.4.6. Rest of Asia-Pacific
10.5. Latin America
- 10.5.1. Brazil
- 10.5.2. Mexico
- 10.5.3. Rest of Latin America
10.6. Middle East & Africa

11. Competition Analysis

11.1. Overview
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Competitive Dashboard
- 11.4.1. Industry Leaders
- 11.4.2. Market Differentiators
- 11.4.3. Vanguards
- 11.4.4. Emerging Companies
11.5. Market Share Analysis/Market Rankings of Key Players (2023)

12. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis*)

12.1. F. Hoffmann-La Roche Ltd (Switzerland)
12.2. Danaher Corporation (U.S.)
12.3. Agilent Technologies, Inc. (U.S.)
12.4. Merck KGaA (Germany)
12.5. Bio-Rad Laboratories, Inc. (U.S.)
12.6. Eagle Biosciences, Inc. (U.S.)
12.7. Thermo Fisher Scientific Inc. (U.S)
12.8. Cell Signaling Technology, Inc. (U.S.)
12.9. PerkinElmer, Inc. (U.S.)
12.10. Bio SB Inc. (U.S.)
12.11. Biocare Medical, LLC. (U.S.)
12.12. Bio-Genex Laboratories (U.S.)
12.13. CANDOR Bioscience GmbH (Germany)
12.14. Innovex Biosciences Inc. (U.S.)

(Note: SWOT analysis of the top 5 companies will be provided.)

13. Appendix

13.1. Available Customization
13.2. Related Reports